NEXM (NexMetals Mining Corp. Common Shares)
Insider Trading Activity
Every open-market purchase and sale reported by NEXM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2010-05-26 | Bassam Damaj | President and CEO | A | — | — |
| 2010-05-26 | VIVIAN H LIU | Executive Vice President | A | — | — |
| 2010-04-13 | Mark Westgate | Vice President & CFO | A | — | — |
| 2010-04-13 | Edward M. Cox | VP of Corp. Development | A | — | — |
| 2010-04-13 | HENRY JEMIL ESBER | EVP Pre-Clinical Business Dev. | A | — | — |
| 2010-04-01 | Rusty Ray | Director | A | — | — |
| 2010-04-01 | RICHARD J BERMAN | Director | A | — | — |
| 2010-04-01 | Roberto Crea | Director | A | — | — |
| 2010-04-01 | Leonard A Oppenheim | Director | A | — | — |
| 2010-03-17 | Edward M. Cox | VP of Corp. Development | A | — | — |
| 2010-03-17 | Bassam Damaj | President and CEO | A | — | — |
| 2010-03-17 | Roberto Crea | Director | A | — | — |
| 2010-03-17 | HENRY JEMIL ESBER | EVP Pre-Clinical Business Dev. | A | — | — |
| 2010-03-11 | RICHARD J BERMAN | Director | Sell | — | — |
| 2010-01-13 | Edward M. Cox | VP of Corp. Development | A | — | — |
| 2010-01-13 | Bassam Damaj | Chief Executive Officer | A | — | — |
| 2010-01-13 | Roberto Crea | Director | A | — | — |
| 2010-01-13 | HENRY JEMIL ESBER | EVP Pre-Clinical Business Dev. | A | — | — |
| 2009-12-18 | Leonard A Oppenheim | Director | Sell | — | — |
| 2009-10-19 | RICHARD J BERMAN | Director | A | — | — |
| 2009-10-19 | Leonard A Oppenheim | Director | A | — | — |
| 2009-10-19 | David S Tierney | Director | A | — | — |
| 2009-10-19 | MARTIN R III WADE | Director | A | — | — |
| 2009-10-19 | ARTHUR D EMIL | Director | A | — | — |
| 2009-08-31 | Hemanshu Pandya | — | Sell | — | — |
| 2009-07-24 | JACOB MAY | — | Sell | — | — |
| 2009-06-11 | Leonard A Oppenheim | Director | A | — | — |
| 2009-06-11 | RICHARD J BERMAN | Director | A | — | — |
| 2009-06-11 | MARTIN R III WADE | Director | A | — | — |
| 2009-06-11 | David S Tierney | Director | A | — | — |
| 2009-06-11 | ARTHUR D EMIL | Director | A | — | — |
| 2009-02-18 | ARTHUR D EMIL | Director | A | — | — |
| 2009-02-18 | David S Tierney | Director | A | — | — |
| 2009-02-18 | MARTIN R III WADE | Director | A | — | — |
| 2009-02-18 | RICHARD J BERMAN | Director | A | — | — |
| 2009-02-18 | Leonard A Oppenheim | Director | A | — | — |
| 2009-02-18 | JACOB MAY | — | Buy | — | — |
| 2009-01-07 | JACOB MAY | — | Buy | — | — |
| 2008-10-14 | JACOB MAY | — | Buy | — | — |
| 2008-10-06 | Mark Westgate | Vice President and CFO | A | — | — |
| 2008-10-06 | Hemanshu Pandya | Vice President and COO | A | — | — |
| 2008-09-17 | Leonard A Oppenheim | Director | A | — | — |
| 2008-09-17 | ARTHUR D EMIL | Director | A | — | — |
| 2008-09-17 | David S Tierney | Director | A | — | — |
| 2008-09-17 | RICHARD J BERMAN | Director | A | — | — |
| 2008-09-10 | Southpoint GP, LLC | 10%+ Owner | Buy | — | — |
| 2008-08-14 | Leonard A Oppenheim | Director | A | — | — |
| 2008-08-14 | Hemanshu Pandya | Vice President and COO | A | — | — |
| 2008-08-14 | ARTHUR D EMIL | Director | A | — | — |
| 2008-08-14 | David S Tierney | Director | A | — | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NEXM quote page; the site-wide leaderboard is on the insider transactions hub.